In a report released today, Joseph Catanzaro from Piper Sandler maintained a Hold rating on Iovance Biotherapeutics (IOVA – Research Report), ...
Truist Securities confirmed its positive stance on Iovance Biotherapeutics (NASDAQ:IOVA) shares, maintaining a Buy rating and a price target of $25.00. With the stock currently trading at $6.07, this ...
Iovance Biotherapeutics Inc (IOVA) stock saw a modest uptick, ending the day at $6.25 which represents a slight increase of $0.06 or 0.97% from the prior close of $6.19. The stock opened at $6.24 and ...
Piper Sandler analyst Joseph Catanzaro lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $7.50 from $10 and keeps a Neutral ...
Technical analysis for Iovance Biotherapeutics Inc. IOVA including support levels resistance levels and stop losses for IOVA ...
Stifel maintains Buy on Iovance stock with $21 target On Monday, Stifel analysts maintained a Buy rating on Iovance Biotherapeutics (NASDAQ:IOVA) with a steady price target of $21.00. According to ...
In trading on Monday, shares of Iovance Biotherapeutics Inc (Symbol: IOVA) entered into oversold territory, hitting an RSI reading of 26.3, after changing hands as low as $5.91 per share.
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Iovance Biotherapeutics (IOVA – Research Report) and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback